Michael Stefanidakis, et al. Development of a Subretinally Delivered CEP290-Specific CRISPR Medicine for the Treatment of Leber Congenital Amaurosis 10 (LCA10), October 19, 2017.

Feb

28

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

Feb

21

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

Jan

31

Editas Medicine to Participate in Upcoming Investor Conferences